Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells

Chinese Journal of Cancer

Volumn 33, Issue 2, 2014, Pages 115-122

  Qiu, Zhi Kun ^a,b,c   Shen, Dong ^a,d   Chen, Yin Sheng ^a,b   Yang, Qun Ying ^a,b   Guo, Cheng Cheng ^a,b   Feng, Bing Hong ^c   Chen, Zhong Ping ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^d South East University Medical College   (China)

Author keywords

Drug resistance; Glioma stem cell; MGMT; NF B; Temozolomide

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DNA METHYLATION; DOWN REGULATION; DRUG SENSITIVITY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IC 50; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GLIOMA; HUMANS; LEUPEPTINS; NEOPLASTIC STEM CELLS; NF-KAPPA B; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;

EID: 84893435197     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10236     Document Type: Article

References (30)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005,352:987-996.
2. Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of longterm temozolomide treatment in patients with high-grade glioma. Neurology, 2007,68: 688-690.
3. Pegg AE. Repair of O(6)-alkylguanine by alkyltransferases. Mutat Res, 2000,462:83-100.
4. Kaina B, Christmann M, Naumann S, et al. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst), 2007,6:1079-1099.
5. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res, 2003,63:5821-5828.
6. Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumor initiating cell. Nature, 2004,432:396-401.
7. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA, 2007,104:10158-10163.
8. Bao S, Wu Q, Mclendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006,444:756-760.
9. Johannessen TC, Wang J, Staftnesmo KO, et al. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathol Appl Neurobiol, 2009,35:380-393.
10. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer, 2006,5:67.
11. Amit S, Ben-Neriah Y. NF-κB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol, 2003,13:15-28.
12. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest, 2001,107:241-246.
13. Huang Q, Zhang QB, Dong J, et al. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer, 2008,8:304.
14. Lavon I, Fuchs D, Zrihan D, et al. Novel mechanism where by nuclear factor kappa B mediates DNA damage repair through regulation of O(6)-methylguanine-DNA-methyltransferase. Cancer Res, 2007,67:8952-8959.
15. Dey M, Ulasov IV, Lesniak MS. Virotherapy against malignant glioma stem cells. Cancer Lett, 2010,289:1-10.
16. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med, 2000,343:1350-1354.
17. Kaina B, Ochs K, Grosch S, et al. BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog Nucl Acid Res Mol Biol, 2001,68:41-54.
18. Liu G, Yuan X, Zeng Z, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer, 2006,5:67.
19. Bredel M, Zentner J. Brain-tumour drug resistance: the bare essentials. Lancet Oncol, 2002,3:397-406.
20. Eramo A, Ricci-Vitiani L, Zeuner A, et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ, 2006,13:1238-1241.
21. Blough MD, Westgate MR, Beauchamp D, et al. Sensitivity to temozolomide in brain tumor initiating cells. Neuro Oncol, 2010,12:756-760.
22. Villalva C, Cortes U, Wager M, et al. O6-methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiationpromoting conditions. Int J Mol Sci, 2012,13:6983-6994.
23. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature, 2008,451:345-349.
24. Schaich M, Kestel L, Pfirrmann M, et al. A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients. Ann Oncol, 2009,20:175-181.
25. Chen HY, Shao CJ, Shi HL, et al. Single nucleotide polymorphisms and expression of ERCC1 and ERCC2 vis-a-vis chemotherapy drug cytotoxicity in human glioma. J Neurooncol, 2007,82:257-262.
26. Chen ZP, Malapetsa A, Monks A, et al. Nucleotide excision repair protein levels vis-à-vis anticancer drug resistance in 60 human tumor cell lines. Chin J Cancer 2002,21:233-239.
27. Cheng L, Bao S, Rich JN. Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol, 2010,80:654-665.
28. Margison GP, Povey AC, Kaina B, et al. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis, 2003,24:625-635.
29. Javanmard S, Loktionova NA, Fang Q, et al. Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-20-deoxygua-nosine and of O(6)-[4-(hydroxymethyl)benzyl] guanine. J Med Chem, 2007,50:5193-5201.
30. Amit S, Ben-Neriah Y. NF-κB activation in cancer: a challenge for ubiquitination-and proteasome-based therapeutic approach. Semin Cancer Biol, 2003,13:15-28.